Home > News > Headline News > Archive

Click on title to read the full article.

Potent metastasis inhibitor identified

June 22, 2009

By Elizabeth Andrews, Boston Children's Hospital

EurekAlert (press release) - Washington,DC,USA
Researchers at Children's Hospital Boston have isolated a potent inhibitor of tumor metastasis made by tumor cells, one that could potentially be harnessed as a cancer treatment.

Identifying the potential for tamoxifen resistance in patients

June 11, 2009

By American Society for Biochemistry and Molecular Biology (ASBMB)

Tamoxifen is a widely used and highly successful drug in the treatment of breast cancer, though resistance to tamoxifen is still a concern in recurrent disease (affecting 25-35% of patients), since therapy resistant metastatic tumour cells are a major cause of death. In a study in this month's Molecular and Cellular Proteomics, researchers have uncovered a protein profile that may accurately predict whether a cancer will be tamoxifen resistant.

Bevacizumab Added to First-Line Chemotherapy Improves Progression

June 2, 2009

By Emma Hitt

DG News - USA
… the Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON-1) on May 31. …

Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer

June 2, 2009

By Frank Hoke, Fox Chase Cancer Center

ORLANDO —Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.

Progress, but no cure reported at major cancer conference

June 1, 2009

By Liz Szabo, USA Today

Study results from the world’s largest cancer conference this weekend highlight both the progress and the frustrations in the fight against cancer.Researchers at the American Society of Clinical Oncology meeting in Orlando say they’re getting closer to their goal of offering patients gentler, more tailored treatments that let them live longer and feel better.

Yet doctors also offered no cures. And even the most highly touted drugs bought patients only a few more months of life.